Actively Recruiting
Improving Vaccine Protection for Older Adults
Led by Singapore General Hospital · Updated on 2026-04-21
40
Participants Needed
1
Research Sites
172 weeks
Total Duration
On this page
Sponsors
S
Singapore General Hospital
Lead Sponsor
A
A*STAR Infectious Diseases Labs
Collaborating Sponsor
AI-Summary
What this Trial Is About
As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.
CONDITIONS
Official Title
Improving Vaccine Protection for Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 21 to 59 years at screening
- BMI between 18.5 and 27.5 kg/m2 according to Asian population guidelines
- Stable health status confirmed by physical exam and medical assessment
- Stable underlying conditions without hospitalization in past 6 months
- Willing and able to provide informed consent
- Committed to attending all study visits and completing study requirements
- Accessible vein in forearm for blood draws
- Female participants must be of non-childbearing potential due to surgery or menopause with at least 12 months of natural amenorrhoea
You will not qualify if you...
- Prior vaccination against yellow fever or dengue, or participation in related vaccine studies
- Prior receipt of AS01-adjuvanted vaccines
- Planned vaccination with AS01-adjuvanted or yellow fever vaccines outside this study during participation
- Illness within 7 days before screening
- History of yellow fever or dengue infection
- Dengue seropositivity at screening
- Smoking history within the last year
- Planned travel to yellow fever endemic areas during the study
- Known allergies to AS01, YF17D vaccine, or components such as egg products
- Diabetes with HbA1c over 6.5
- Medical conditions posing risk to intramuscular injections
- Immunodeficiency or related immune disorders
- Recent use of anti-inflammatory drugs in past 7 days
- Use of metformin in last month
- Use of corticosteroids above specified doses in past 6 months
- Use of biologics in past 12 months
- Conditions that may complicate study participation or safety
- Evidence of substance abuse
- Clinically significant anemia (Hb under 10 g/dL)
- Blood donation over 450 ml in past 3 months
- Participation in other investigational studies within past 4 months
- Receipt of any licensed vaccine within 30 days before or after study vaccination
- Receipt of immunoglobulin or blood products within 90 days prior to first vaccine dose or planned during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Singapore General Hospital
Singapore, Singapore, 169608
Actively Recruiting
Research Team
C
Candice Y.Y. Chan, MBChB, MRCP
CONTACT
C
Christina Titin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here